#REMEDi4ALL is stepping away from this platform to focus on channels that align with our audience needs. Stay connected with us for the latest in medicines repurposing on our website, LinkedIn, Bluesky, Facebook & YouTube.
Thank you for the support! 💊
⏰LAST CHANCE ⏰ #iDR26 early bird tickets close tomorrow!
Join the leading international conference on drug repurposing and engage with global experts shaping the future of patient-centric medicines.
🎟️ Get your early bird ticket here: https://t.co/5k2hmpjILZ
📣 Learn from the diverse strategies and approaches in Drug Repurposing at #iDR26!
Join us to connect, share knowledge, and navigate the future of medicines repurposing.
🔗 Learn more and register for an early bird ticket by 31 Jan here: https://t.co/5k2hmpjILZ
🆕Updated: REMEDi4ALL guide to creating joint calls for impactful drug repurposing research
Joint calls enable cross-border projects, increase available funding, and combine funder expertise for greater impact.
Explore the latest updates to the guide ➡️ https://t.co/fYHvZsUzmn
⏰It’s official: the #iDR26 Programme has landed!
From rare diseases and AI-driven discovery to policy, funding and community-led success stories, #iDR26 brings key stakeholders together for patient impact.
🎟️Early bird tickets available until 31 Jan➡️https://t.co/UvpD7MuxBo
🔍 Did you know REMEDi4ALL offers practical resources for in-silico drug repurposing research?
From a DR catalogue and expert publications to SOPs and an expertise dashboard, these tools help academics work efficiently and collaboratively.
🔗 https://t.co/0F5cEB2H99
🌐New REMEDi4ALL Funders Network members: 14 new members have joined the REMEDi4ALL Funders Network this year!
🤝The network brings global funders together to collaborate, share best practices & support drug repurposing research.
Find out more ➡️ https://t.co/yVF9fzwp51
⏰REMEDi4ALL Academic Bootcamp deadline extended - limited places still remain!⏰
Join the REMEDi4ALL Academic Bootcamp (11–12 Mar 2026, Cambridge, UK) for hands-on drug repurposing training. Fully funded for selected participants.
📅 Apply now ➡️ https://t.co/nGd389rG20
🚨 Today is the deadline to submit your abstract for the #iDR26 Poster Session!
Showcase your work, stories, and experiences to an international audience of professionals and thought leaders in the drug repurposing field!
👉 Submit your abstract here: https://t.co/pruVJ5l2eH
Bursaries available for patients and patient representatives at #iDR26!
Participants may be granted financial support to cover travel, accommodation, and ticketing.
👉 Learn more about patient bursaries here: https://t.co/d5NUC0Pf2H
💊 Could an existing medicine help people living with Osteogenesis Imperfecta, and could you take part?
The REMEDi4ALL MOI-A study is recruiting patients to explore whether repurposing losartan could benefit people living with OI.
📽️ More: https://t.co/9RJbLrzbzh
⏳ REMEDi4ALL Academic Bootcamp: applications close tomorrow!
Last chance to apply for the REMEDi4ALL Academic Bootcamp (11–12 March 2026, Cambridge, UK) and get expert support to advance your drug repurposing idea.
🗓️ Deadline: 14 Jan
🔗 https://t.co/nGd389rG20
⏳1 week to go until applications close!
Don’t miss your chance to join the REMEDi4ALL Academic Bootcamp (11–12 March 2026, Cambridge, UK) and take your drug repurposing idea to the next stage with expert support.
🗓️Applications close 14 Jan
🔗Register: https://t.co/nGd389rG20
🧭 Join the global drug repurposing community at #iDR26 and contribute your work or perspective.
Take part by submitting an abstract for the Poster Session or by applying for a Lightning Talk. Read more and find the deadlines below!
➡️ Apply here: https://t.co/pruVJ5l2eH
💊Interested in taking your #DrugRepurposing idea to the next level?
🔬 Join the REMEDi4ALL Academic Bootcamp on 11–12 March 2026 in Cambridge, UK: a hands-on programme to help researchers advance promising repurposing concepts.
⌛ Apply by 14 Jan: https://t.co/nGd389rG20
📚New from REMEDi4ALL demonstrator project: Can an existing blood pressure medicine improve bone health in osteogenesis imperfecta?
A phase II trial is #repurposing losartan to target overactive TGFβ signalling in adolescents & adults with OI.
🔗 https://t.co/cL7RMHNjzP
❄️ Season’s greetings from #REMEDi4ALL! We are grateful for your support in advancing drug repurposing and look forward to continued impact in the year ahead.
🚨Breaking! #iDR26 is excited to announce our four conference tracks for this year🚨
🌐Rare Diseases
🔍Discovery
💼Industry
👥Community
Interested in learning more about these key areas in drug repurposing? Join us on 12-13 May in Brussels➡️ https://t.co/5k2hmpjILZ
Prof. Irena Mlinarič Raščan, University of Ljubljana, was recently featured in DELO, Slovenia’s largest daily newspaper, in an in-depth article exploring the future of drug repurposing and her work with #REMEDi4ALL.
🔗 Read the article here: https://t.co/gh4nGkIg9F
🔍New open-access REMEDi4ALL resource for in silico drug repurposing!
Two annotation workflows (KNIME + Python/Neo4j) help extract, harmonise & explore chemical and bioactivity data across >5000 compounds for drug repurposing!
🔗Read the article➡️ https://t.co/gmS7BnfgKP